Boshi Huang

2.2k citations

69 papers · 1.7k indexed · h-index 23

Co-authors: Xinyong Liu Peng Zhan Dongwei Kang Erik De Clercq Christophe Pannecouque Dirk Daelemans Xueshun WangYan Zhang
Topics: HIV/AIDS drug development and treatment (37 papers)HIV Research and Treatment (30 papers)Click Chemistry and Applications (18 papers)
Cited by: Virology Infectious Diseases Organic Chemistry
Journals: Scientific Reports Journal of Medicinal Chemistry Journal of Pharmacology and Experimental Therapeutics
Partner nations: China Belgium United States

In The Last Decade

Boshi Huang

69 papers receiving 1.7k citations

Peers

Countries citing papers authored by Boshi Huang

Since Specialization

Citations

This map shows the geographic impact of Boshi Huang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Boshi Huang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Boshi Huang more than expected).

Fields of papers citing papers by Boshi Huang

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Boshi Huang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Boshi Huang. The network helps show where Boshi Huang may publish in the future.

Co-authorship network of co-authors of Boshi Huang

This figure shows the co-authorship network connecting the top 25 collaborators of Boshi Huang. A scholar is included among the top collaborators of Boshi Huang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Boshi Huang. Boshi Huang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Identification of novel diarylpyrimidine derivatives as potent HIV-1 non-nucleoside reverse transcriptase inhibitors against wild-type and K103N mutant viruses 2024 ·European Journal of Medicinal Chemistry ·Xiangyi Jiang,Waleed A. Zalloum,Zhen Gao,(unknown),(unknown),Minghui Xie,(unknown),Erik De Clercq,Boshi Huang,Christophe Pannecouque,Peng Zhan,Xinyong Liu	2
2	Discovery of novel fused-heterocycle-bearing diarypyrimidine derivatives as HIV-1 potent NNRTIs targeting tolerant region I for enhanced antiviral activity and resistance profile 2024 ·European Journal of Medicinal Chemistry ·(unknown),Xiangyi Jiang,Heng Gao,Boshi Huang,Erik De Clercq,Christophe Pannecouque,Shaoqing Du,Xinyong Liu,(unknown)	2
3	NCP, a Dual Kappa and Mu Opioid Receptor Agonist, Is a Potent Analgesic Against Inflammatory Pain without Reinforcing or Aversive Properties 2024 ·Journal of Pharmacology and Experimental Therapeutics ·Peng Huang,(unknown),(unknown),Saadet Inan,Scott M. Rawls,Mengchu Li,Boshi Huang,Piyusha P. Pagare,E. Andrew Townsend,Justin L. Poklis,Matthew S. Halquist,Matthew L. Banks,Yan Zhang,Lee‐Yuan Liu‐Chen	2
4	Discovery of GluN2A subtype-selective N-methyl-d-aspartate (NMDA) receptor ligands 2024 ·Acta Pharmaceutica Sinica B ·(unknown),Na Liu,Fabao Zhao,Boshi Huang,Dongwei Kang,Peng Zhan,(unknown)	6
5	Discovery of novel diarypyrimidine derivatives bearing six-membered non-aromatic heterocycles as potent HIV-1 NNRTIs with improved anti-resistance and drug-like profiles 2023 ·European Journal of Medicinal Chemistry ·Xiangyi Jiang,Boshi Huang,Waleed A. Zalloum,Chin‐Ho Chen,(unknown),Zhen Gao,(unknown),Minghui Xie,Dongwei Kang,Erik De Clercq,Christophe Pannecouque,Xinyong Liu,Peng Zhan	7
6	Discovery of diarylpyrimidine derivatives bearing piperazine sulfonyl as potent HIV-1 nonnucleoside reverse transcriptase inhibitors 2023 ·Communications Chemistry ·Xiangyi Jiang,Boshi Huang,(unknown),(unknown),Waleed A. Zalloum,Dongwei Kang,Fabao Zhao,(unknown),Zhen Gao,(unknown),Zhao Wang,Minghui Xie,Erik De Clercq,Francesc X. Ruiz,Eddy Arnold,Christophe Pannecouque,Xinyong Liu,Peng Zhan	16
7	Design, Synthesis, and Antisickling Investigation of a Nitric Oxide-Releasing Prodrug of 5HMF for the Treatment of Sickle Cell Disease 2022 ·Biomolecules ·(unknown),Mohini S. Ghatge,(unknown),(unknown),(unknown),(unknown),Richmond Danso‐Danquah,Boshi Huang,Yan Zhang,Faik N. Musayev,Osheiza Abdulmalik,Martin K. Safo	6
8	Newly Emerging Strategies in Antiviral Drug Discovery: Dedicated to Prof. Dr. Erik De Clercq on Occasion of His 80th Anniversary 2022 ·Molecules ·Shujing Xu,(unknown),Xujie Zhang,Lin Sun,Dongwei Kang,Boshi Huang,Xinyong Liu,Peng Zhan	22
9	Structure-Based Design and Discovery of Pyridyl-Bearing Fused Bicyclic HIV-1 Inhibitors: Synthesis, Biological Characterization, and Molecular Modeling Studies 2021 ·Journal of Medicinal Chemistry ·Boshi Huang,Tiziana Ginex,F. Javier Luque,Xiangyi Jiang,Ping Gao,Jian Zhang,Dongwei Kang,Dirk Daelemans,Erik De Clercq,Christophe Pannecouque,Peng Zhan,Xinyong Liu	13
10	Discovery of potential dual-target prodrugs of HIV-1 reverse transcriptase and nucleocapsid protein 7 2020 ·Bioorganic & Medicinal Chemistry Letters ·(unknown),Boshi Huang,Zhuo Li,Zhao Wang,Lin Sun,Ping Gao,Dongwei Kang,Chin‐Ho Chen,Kuo‐Hsiung Lee,Dirk Daelemans,Erik De Clercq,Christophe Pannecouque,Peng Zhan,Xinyong Liu	3
11	Recent advances in multitarget-directed ligands targeting G-protein-coupled receptors 2020 ·Drug Discovery Today ·(unknown),Boshi Huang,Yan Zhang	25
12	Discovery of piperidine-substituted thiazolo[5,4-d]pyrimidine derivatives as potent and orally bioavailable HIV-1 non-nucleoside reverse transcriptase inhibitors 2019 ·Communications Chemistry ·Dongwei Kang,Tong Zhao,Zhao Wang,Da Feng,Heng Zhang,Boshi Huang,Gaochan Wu,Fenju Wei,Zhongxia Zhou,Lanlan Jing,(unknown),Ye Tian,Vasanthanathan Poongavanam,Jacob Kongsted,Erik De Clercq,Christophe Pannecouque,Peng Zhan,Xinyong Liu	29
13	Exploiting the Tolerant Region I of the Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) Binding Pocket: Discovery of Potent Diarylpyrimidine-Typed HIV-1 NNRTIs against Wild-Type and E138K Mutant Virus with Significantly Improved Water Solubility and Favorable Safety Profiles 2019 ·Journal of Medicinal Chemistry ·Boshi Huang,Wen‐Ming Chen,Tong Zhao,Zhenyu Li,Xiangyi Jiang,Tiziana Ginex,David Vı́lchez,F. Javier Luque,Dongwei Kang,Ping Gao,Jian Zhang,Ye Tian,Dirk Daelemans,Erik De Clercq,Christophe Pannecouque,Peng Zhan,Xinyong Liu	71
14	Further Exploring Solvent-Exposed Tolerant Regions of Allosteric Binding Pocket for Novel HIV-1 NNRTIs Discovery 2018 ·ACS Medicinal Chemistry Letters ·Dongwei Kang,Zhao Wang,Heng Zhang,Gaochan Wu,Tong Zhao,Zhongxia Zhou,Zhipeng Huo,Boshi Huang,Da Feng,Xiao Ding,Jian Zhang,(unknown),Lanlan Jing,Wei Luo,(unknown),Dirk Daelemans,Erik De Clercq,Christophe Pannecouque,Peng Zhan,Xinyong Liu	29
15	Design, synthesis and biological evaluation of tacrine-1,2,3-triazole derivatives as potent cholinesterase inhibitors 2017 ·MedChemComm ·Gaochan Wu,Yun Gao,Dongwei Kang,Boshi Huang,Zhipeng Huo,Huiqing Liu,Vasanthanathan Poongavanam,Peng Zhan,Xinyong Liu	61
16	Structure-Based Optimization of Thiophene[3,2-d]pyrimidine Derivatives as Potent HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Improved Potency against Resistance-Associated Variants 2017 ·Journal of Medicinal Chemistry ·Dongwei Kang,Zengjun Fang,Boshi Huang,Xueyi Lu,Heng Zhang,Haoran Xu,Zhipeng Huo,Zhongxia Zhou,(unknown),(unknown),Gaochan Wu,Xiao Ding,Ye Tian,Dirk Daelemans,Erik De Clercq,Christophe Pannecouque,Peng Zhan,Xinyong Liu	84
17	Design, synthesis and anti-HIV evaluation of novel diarylpyridine derivatives as potent HIV-1 NNRTIs 2017 ·European Journal of Medicinal Chemistry ·Zhaoqiang Liu,Ye Tian,Jinghan Liu,Boshi Huang,Dongwei Kang,Erik De Clercq,Dirk Daelemans,Christophe Pannecouque,Peng Zhan,Xinyong Liu	13
18	Fused heterocycles bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 3: Optimization of [1,2,4]triazolo[1,5-a]pyrimidine core via structure-based and physicochemical property-driven approaches 2015 ·European Journal of Medicinal Chemistry ·Boshi Huang,Cuicui Li,Wen‐Ming Chen,Tao Liu,(unknown),Lu Fu,(unknown),Huiqing Liu,Erik De Clercq,Christophe Pannecouque,Jan Balzarini,Peng Zhan,Xinyong Liu	82
19	Design, synthesis and anti-HIV evaluation of novel diarylpyridine derivatives targeting the entrance channel of NNRTI binding pocket 2015 ·European Journal of Medicinal Chemistry ·Jiapei Yang,Wen‐Ming Chen,Dongwei Kang,Xueyi Lu,Xiao Li,Zhaoqiang Liu,Boshi Huang,Dirk Daelemans,Christophe Pannecouque,Erik De Clercq,Peng Zhan,Xinyong Liu	28
20	Anti-human immunodeficiency virus (anti-HIV) natural products with special emphasis on HIV reverse transcriptase inhibitors 1997 ·Life Sciences ·T.B. Ng,Boshi Huang,Wing‐Ping Fong,H.W. Yeung	110

About Boshi Huang

Boshi Huang is a scholar working on Virology, Infectious Diseases and Organic Chemistry, having authored 69 papers that have together received 1.7k indexed citations. Recurring topics across this work include HIV/AIDS drug development and treatment (37 papers), HIV Research and Treatment (30 papers) and Click Chemistry and Applications (18 papers). The work is most often cited by research in Virology (570 citations), Infectious Diseases (724 citations) and Organic Chemistry (669 citations). Boshi Huang has collaborated with scholars based in China, Belgium and United States. Frequent co-authors include Xinyong Liu, Peng Zhan, Dongwei Kang, Erik De Clercq, Christophe Pannecouque, Dirk Daelemans, Xueshun Wang, Yan Zhang, Zhongxia Zhou and T.B. Ng. Their work appears in journals such as Scientific Reports, Journal of Medicinal Chemistry and Journal of Pharmacology and Experimental Therapeutics.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact